title: [Androgen deprivation in benign prostatic hypertrophy].
abstract: Benign prostatic hypertrophy is the cause of urinary outflow obstruction in the majority of men older than 50 years. Even if the pathophysiology of BPH is multifactorial, its development needs testicular androgens and aging. Androgen deprivation is the only approach that may reduce the hyperplastic state. This article reviews the endocrine aspect of BPH and the various hormonal treatment strategies, concerning clinical efficacy and side effects.
authors.affiliation: Division of Urology, University G. D'Annunzio Medical School, Chieli, Italie.
authors.forename: R
authors.initials: R
authors.lastname: Tenaglia
authors.forename: M
authors.initials: M
authors.lastname: Nicolai
authors.forename: G
authors.initials: G
authors.lastname: Di Federico
authors.forename: R
authors.initials: R
authors.lastname: Iantorno
authors.forename: A
authors.initials: A
authors.lastname: Zezza
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
mesh_terms: D000328:Adult; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D045167:Progesterone Congeners / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery
chemical_list: D000726:Androgen Antagonists; D045167:Progesterone Congeners; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate